There are few contraindications to electroconvulsive therapy and it is generally well tolerated. However, electro convulsive therapy in elderly patients with cardiac pacemakers in situ theoretically presents an increased risk of complications. We undertook a retrospective audit of all patients who received anaesthesia for electroconvulsive therapy between January 1999 and September 2005. There were ten patients who had cardiac pacemakers in situ. They underwent a total of 147 electroconvulsive therapy treatments. In 146 out of the 147 treatments, the anaesthesia proceeded uneventfully. The findings suggest that provision of anaesthesia and electroconvulsive therapy in patients with cardiac pacemakers, including rateresponsive pacemakers, is a safe undertaking, with no extra precautions being needed except for routine ECG monitoring.
The provision of general anaesthesia for the purpose of conducting electroconvulsive therapy (ECT) is a common occurrence. In general, it is well tolerated and a number of studies have confirmed that it is a safe procedure with relatively few contraindications. however, as medical technology has progressed, new challenges have arisen. one issue that has arisen is whether ECT can be safely given in the presence of a cardiac pacemaker and whether any special precautions need to be followed in administering anaesthesia and ECT to this patient group. In patients with older pacemakers, there is some concern that the electrical stimulus administered may in some way interfere with the pacemaker function, similar to that which can occur with some types of diathermy. others have raised concerns that with newer, so-called rateresponsive pacemakers, excessive patient movement, or even relaxant-induced fasciculations, could induce changes in pacemaker function.
The aim of the study was to ascertain whether patients who had cardiac pacemakers in situ and who underwent anaesthesia and ECT presented any specific anaesthetic risks or cardiac complications as a result of undergoing the procedure.
METhoDs
With Ethics Committees approval (northern sydney health, Ramsay healthcare and hope healthcare) a retrospective audit of all patients who underwent ECT from January 1999 through september 2005 was undertaken. The records of all patients who satisfied the three criteria for inclusion in the study (cardiac pacemaker in situ, underwent ECT and had a general anaesthetic) were examined.
In addition to demographic data (age, gender), information was gathered on the cardiac pacemaker (type of device and reason for insertion), current cardiac medications, ECT (dose, electrode placement, and duration of electroencephalograph (EEG) and motor seizure), anaesthesia technique and complications.
The conduct of anaesthesia followed our standard practice. standard monitoring (pulse oximetry and ECG) was used in all cases and continued from the period prior to induction until transfer to the recovery area. Anaesthesia was usually induced with thiopentone, but in a small number of cases, with propofol. Muscle relaxation was achieved using suxamethonium. After induction of anaesthesia and appropriate muscle relaxation, the ECT stimulus was applied. Following cessation of the seizure and return of spontaneous ventilation, patients were transferred to an adjacent recovery area, where routine measurements of oxygen saturation, heart rate and blood pressure were undertaken at regular intervals (until these parameters had returned to within 20% of pre-ECT levels and the patient had regained consciousness).
REsULTs
The demographic data and details of anaesthetic and ECT treatments are shown in Tables 1 and 2 . There were ten patients who satisfied the inclusion criteria. These underwent a combined total of 147 treatments. The mean age of the patients was 81.5 years (sD 6.1 years) with a female preponderance (7:3). Most patients were taking concomitant cardiovascular medications. With regard to the pacemakers, dual chamber pacemakers were found in all patients in this study and all but one had a rate-responsive device. They had been inserted for a range of conditions including heart block and sick sinus syndrome.
Assessment of the occurrence of complications was assessed by a detailed examination of the anaesthetic record, observations from the period spent in recovery and the patient's medical record. At the conclusion of the anaesthetic, our routine practice is that the attending anaesthetist is required to note any untoward events on the anaesthetic chart. Also, in the recovery period, any untoward events, and especially those requiring any intervention are noted by nursing staff on the recovery chart. The absence of any notation in these areas was taken as reflecting an uneventful anaesthetic. on all but one occasion, ECT and associated anaesthesia were uneventful with no recorded compromise in either pacemaker function or cardiovascular stability. Details of the single adverse event are presented in the following case report.
Case history
An 86-year-old female (case 1 in Tables 1 and 2) The patient was given atropine IV (0.6 mg×2) and with no ECG trace still visible, adrenaline 2 ml of 1:10,000 solution was also given. This resulted in the appearance of sinus tachycardia (220 bpm) and a blood pressure of 200/140 mmhg. Boluses of hydralazine 8 mg and esmolol 10 mg controlled the rate and lowered the blood pressure to 150/90 mmhg. The patient was transferred to a general medical institution where she was found to be in atrial fibrillation, with intermittent paced beats. The pacemaker was checked and found to be functional but was changed to VVIR mode. Attending medical staff suggested that the initial diagnosis of asystole may have been an artefact due to an improperly attached ECG lead. The patient went on to have two further uneventful ECT procedures. Whether this incident was due to ECT-induced pacemaker malfunction cannot be determined.
DIsCUssIon since its introduction into psychiatric practice over 60 years ago, ECT has been shown to be an effective treatment for depression, particularly in the elderly 1 , in whom it is often the treatment of choice. Thus the patient group receiving ECT often have multiple medical co-morbidities. Fortunately, most may have ECT safely 2,3 . however, for patients presenting for ECT with cardiac pacemakers in situ there is at present no clear consensus to the optimal mode for safe pacing during ECT.
The American College of Cardiologists/American heart Association has established guidelines for the pre-anaesthetic assessment of patients with pacemakers presenting for ECT 4, 5 . These include a thorough medical assessment of co-morbidities, assessment of the reasons for pacemaker insertion and interrogation of pacemaker function by appropriately trained technicians 4 . Common reasons for pacemaker insertion include symptomatic sinus bradycardia, sinus node dysfunction, symptomatic atrioventricular node disease, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and long QT syndrome 4 .
Anaesthetists should always be prepared to deal with pacemaker failure, which can occur due to device failure, lead failure, or failure of capture (due to acid-base disturbances, electrolyte changes or ischaemia, all of which alter pacing thresholds) 5, 6 . This may be achieved through either pharmacological or physical means. Consequently, atropine and beta sympathomimetic drugs such as isoprenaline or ephedrine should always be available. While the ability to externally pace a patient in the case of complete pacemaker failure could be lifesaving, the use of this modality obviously depends on both the availability of the appropriate equipment and importantly, staff trained in its use. As it is unlikely that these criteria could be easily met, this type of intervention is not routinely recommended.
Although it is advised that a magnet is available whilst a patient with a pacemaker is undergoing anaesthesia, the response of pacemakers to magnets varies considerably, depending on the make and model of the device 5, 6 . A magnet may have no effect, a transient or continuous loss of pacing or a reversion to asynchronous pacing. The actual response of the pacemaker also depends on battery life. hence it is important that the device is assessed by the appropriate manufacturer and that the clinician understands the response of that pacemaker to a magnet 5, 6 .
There is debate at present as to the most appropriate mode that a pacemaker should be programmed for ECT. Current guidelines continue to advise that pacemakers should be reprogrammed to the asynchronous mode for ECT to protect against under-or over-sensing from electromagnetic interference 6, 7 . It has also been suggested that all rateresponsiveness should be disabled for ECT 6 , probably because of concerns that movement associated with ECT could be sensed by the pacemaker, which could then pace in an abnormal manner.
originally, concern for performing ECT in patients with cardiac pacemakers was mainly focused on the electrical charge delivered during ECT which could theoretically interfere with the pacemaker circuitry or cardiac function per se. however in more recent times, most pacemakers tend to be of the "rateresponsive" type, where the pacemaker responds to a number of physiological variables such as chest wall impedance or respiratory rate. This has raised the further problem that manual ventilation, excessive movement due to inadequate relaxation, or even fasciculations secondary to suxamethonium could interfere with function. however, apart from possible historic precedent, there is no clinical basis for these concerns. A recent report by Giltay and colleagues examined the intracardiac electrical currents in response to ECT in a single patient with a VDDR pacemaker 8 . Although ECT delivers approximately 50-100J of energy, with a voltage of approximately 150-200V, using intracardiac electrodes they were able to demonstrate noise signals within the heart of around 2mV 8, 9 . This caused transient over-sensing in the atrium with no adverse clinically relevant sequelae reported. Furthermore pacemaker function normalized immediately after ECT.
There have been several single case reports and one recent retrospective review of pacemakers and ECT 7, 10-13 . Importantly, none of these have attributed pacemaker dysfunction to ECT.
More recently, Dolenc and colleagues reported a study which constituted a retrospective case series of patients with pacemakers and implantable cardioverter/defibrillators undergoing ECT 12 . In 29 patients with a total of 493 treatments, no patient had any evidence of disturbance of pacemaker function that was related to ECT. Pacemaker settings were not altered prior to ECT, although they did obtain preand post-ECT assessment of each patient's medical condition and pacemaker function, by an appropriate physician. some authors also advise disabling rate-responsive components of pacemakers for all general anaesthesia 6 , however others suggest that rate-modulation may be safely left on 5 . Certainly, pacing at inappropriate rates under anaesthesia due to electromagnetic interference from diathermy or monitoring devices has been reported with rate-responsive pacemakers [14] [15] [16] [17] [18] . In this series of patients, there was no interference or re-programming of pacemakers undertaken, suggesting that with modern pacemakers, interference by either electrical stimulus or patient movement does not interfere with function. Pacemaker failure has also been associated with suxamethoniuminduced muscle fasciculations 19 . however in the series by Dolenc and colleagues, no documented cases of inappropriate rate modulation due to ECT or to suxamethonium were reported, suggesting that this may be less of a concern with the current generation of pacemakers. In this series no special precautions were undertaken, and no complications clearly attributable to ECT ensued, which suggests that there is no requirement to alter the function of rate responsive devices.
In our study, we examined the individual records of 10 patients who underwent 147 treatments in total over a four-year period. ECG monitoring was used as a routine, but apart from that no alteration with the normal conduct of ECT or anaesthesia was undertaken. There was only one case where the patient was reported as having post ECT asystole/ bradycardia and in any event the patient was treated successfully (see Case history). Interestingly, it could be argued that having a cardiac pacemaker in situ may to some degree be protective, since it is known that ECT per se, especially when delivered using the bifrontotemporal electrode position, can result in a significant cholinergic surge with subsequent severe bradycardia or even asystole 20, 21 .
The results of our series suggest that ECT and general anaesthesia in patients with cardiac pacemakers is not associated with any clear increased anaesthetic risk or cardiac complications. Apart from routine checking of pacemaker function prior to treatment and the use of ECG monitoring, no special interventions appear to be necessary.
